Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Inc.

Medicare payments are a big source of revenue for health insurers. 


HUM, UNH, CVS: Healthcare Stocks Soar on 2.48% Medicare Rate Increase

Bernstein analyst Courtney Breen maintained a Buy rating on Humana yesterday and set a price target of $211.00. According to TipRanks, Breen is a 4...

Bernstein Sticks to Its Buy Rating for Humana (HUM)

Humana AB ( ($SE:HUM) ) has shared an update. Humana AB has called its annual general meeting for May 7, 2026, in Stockholm, setting out how shareh...

Humana sets May 7, 2026 AGM with expanded postal voting options

An announcement from Hua Medicine ( ($HK:2552) ) is now available. Hua Medicine reported rapid commercial growth in 2025 as it took over marketing ...

Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin

Hua Medicine ( ($HK:2552) ) just unveiled an update. Hua Medicine has announced a change in its corporate secretarial leadership, with Ms. Yuen Win...

Hua Medicine Reshuffles Company Secretary and Authorised Representative Roles

Humm Group Limited ( ($AU:HUM) ) has provided an announcement. Humm Group Limited has applied to the ASX for quotation of 4,841,475 new fully paid ...

Humm Group Seeks ASX Quotation for New Dividend Plan Shares

Hua Medicine ( ($HK:2552) ) has shared an announcement. Hua Medicine has announced that it will relocate its principal place of business in Hong Ko...

Hua Medicine Relocates Hong Kong Principal Place of Business

An announcement from Humm Group Limited ( ($AU:HUM) ) is now available. Humm Group Limited has acknowledged that the Takeovers Panel has received a...

Humm Group Flags Takeovers Panel Review Bid by Major Shareholder

This week, several dividend stocks are trading close to their 52-week lows. Here is a list of ten such stocks that are also reaching their ex-divid...

Ex-Dividend Date Nearing for These 10 Stocks – Week of March 23, 2026

Humm Group Limited ( ($AU:HUM) ) has shared an update. The Takeovers Panel has received an application from major shareholder Andrew Abercrombie se...

Takeovers Panel Receives Review Bid Over Humm Group Ruling

Humacyte ( ($HUMA) ) has provided an update. On March 19, 2026, Humacyte suspended and terminated its at-the-market equity prospectus for up to $60...

Humacyte Ends ATM Program, Highlights Symvess Global Expansion

Humm Group Limited ( ($AU:HUM) ) has provided an update. Australia’s Takeovers Panel has declared unacceptable circumstances in relation to Humm Gr...

Takeovers Panel raps Humm Group over misleading bid disclosures and chair’s share buys

An update from Hua Medicine ( ($HK:2552) ) is now available. Hua Medicine has scheduled a board meeting for March 26, 2026 to review and approve th...

Hua Medicine Sets March 26 Board Meeting to Approve 2025 Results

These companies have underperformed peers in their sectors. 


These Are the Stocks Most Likely to Be Targeted by Activist Investors, Says Wolfe Research

Humm Group Limited ( ($AU:HUM) ) just unveiled an announcement. Australia’s Takeovers Panel has issued further interim orders relating to Humm Grou...

Takeovers Panel Orders Further Delay to Humm Group Shareholder Meeting Amid Control Dispute

Humana AB ( ($SE:HUM) ) has issued an announcement. Humana has agreed to acquire Homsan AB, a Stockholm-region provider of daily activities under L...

Humana to Double LSS Daily Activity Services with Homsan Acquisition

Humana ( ($HUM) ) has shared an update. On March 5, 2026, Humana entered an underwriting agreement with a syndicate led by Goldman Sachs and J.P. M...

Humana Issues $1 Billion Junior Subordinated Notes Offering

Humm Group Limited ( ($AU:HUM) ) has shared an update. Humm Group has confirmed that it is close to finalising a confidentiality deed with Credit C...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUM	$182.30	+2.51%	885.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUM	$182.30	+2.5%	885.12K
3
4
5
6

HUM

HUM

Get Humana Inc. Data in Excel

Get Humana Inc. Data in Excel